Rockville, Maryland, United States – September 9, 2026 – The U.S. Food and Drug Administration’s guidance on electronic systems and records in clinical investigations emphasizes that computerized systems used to create, maintain, retrieve, and transmit clinical data must support trustworthy and reliable records. In August 2026, the FDA also highlighted digitally derived endpoints and digital health technologies as part of its ongoing work to modernize clinical-trial data collection.

According to Fact.MR, the global electronic data capture systems market is valued at USD 2.7 billion in 2026 and is projected to reach USD 7.4 billion by 2036, expanding at a 10.6% CAGR. The market was valued at USD 2.4 billion in 2025, creating an estimated absolute opportunity of USD 4.7 billion during the forecast period.

Get detailed market forecasts, competitive benchmarking, and pricing trends:https://www.factmr.com/connectus/sample?flag=S&rep_id=15971

Why Electronic Data Capture Is Becoming Core Trial Infrastructure

Clinical trials generate participant information, laboratory results, investigator assessments, safety records, and other protocol-defined data across multiple locations.

Electronic data capture systems replace paper-based case report forms with structured digital workflows. Investigators can enter information directly into electronic case report forms, while sponsors and data managers can review study progress remotely.

The operational impact extends beyond eliminating paper.

Modern EDC platforms can incorporate validation rules, automated queries, role-based permissions, audit trails, and controlled access. These capabilities help trial teams identify incomplete or inconsistent information before database lock.

The FDA notes that computerized clinical-trial systems create and maintain data that can form the basis for regulatory decisions on drugs, biologics, and medical devices, making data quality and integrity central considerations for sponsors and investigators.

Cloud-Based EDC Platforms Hold the Largest Solution Share

Cloud-based EDC platforms are projected to account for 42.0% of the solution-type segment in 2026, making them the leading category.

Clinical trials frequently involve research sites operating across different cities and countries. Cloud infrastructure allows authorized investigators, monitors, sponsors, and data managers to access a centralized environment without deploying separate local servers at each site.

Centralized architecture can also simplify software updates and study configuration.

For multinational trials, this becomes particularly relevant because sponsors need consistent electronic case report forms and data-management procedures across participating centers.

Security and validation remain essential. Cloud deployment does not remove the requirement for appropriate access controls, auditability, system validation, and data governance.

Clinical Trial Data Management Leads Application Demand

Clinical Trial Data Management is projected to represent 44.0% of the clinical-application segment in 2026.

EDC platforms sit at the center of structured trial-data collection. Data managers use these systems to monitor entries, issue queries, track corrections, and prepare datasets for statistical analysis.

Automated edit checks can identify missing or inconsistent information when data are entered rather than waiting until a later manual review.

This can shorten the time required to identify discrepancies and improve visibility into study progress.

Integration is becoming another important requirement. Sponsors increasingly seek connections between EDC systems and electronic health records, randomization platforms, electronic patient-reported outcomes, laboratory systems, and other clinical technologies.

Pharmaceutical Companies Remain the Largest End Users

Pharmaceutical companies are expected to account for 46.0% of the end-use industry segment in 2026.

Drug developers use EDC systems across clinical-development programs, from early-stage studies through larger confirmatory trials and post-market research.

The scale of pharmaceutical clinical-development portfolios creates demand for platforms capable of handling multiple protocols while maintaining consistent data-management controls.

The regulatory significance is substantial. Clinical-trial data submitted to agencies must demonstrate reliability and integrity, placing EDC validation and governance alongside study design and statistical analysis as core development considerations.

CROs Account for the Largest User Category

Clinical Research Organizations are projected to represent 43.0% of the user-category segment in 2026.

CROs operate clinical data-management functions across multiple sponsor programs. A configurable EDC platform allows them to build electronic case report forms, manage queries, oversee sites, and support different protocols within a controlled technology environment.

The ability to reuse workflows and configure studies without rebuilding an entire technology stack can improve operational efficiency.

For CROs, platform selection also affects sponsor relationships. They need systems that can provide clear audit histories, controlled user permissions, reliable exports, and integration with other trial-management technologies.

SaaS Deployment Takes the Lead

SaaS deployment is forecast to account for 41.0% of the deployment-model segment in 2026.

SaaS enables sponsors and CROs to establish an EDC environment for an individual study without purchasing permanent local infrastructure.

Capacity and user access can be adjusted as research sites are activated, expanded, or closed.

This model is particularly useful for trials spanning several countries because software versions and configurations can be managed centrally.

For procurement teams, however, SaaS selection involves more than subscription pricing. Validation documentation, cybersecurity, data residency, interoperability, service-level commitments, disaster recovery, and audit readiness can influence total cost and vendor selection.

What Is Driving Market Expansion?

The transition from paper-based clinical records remains a foundational growth factor.

Regulatory requirements provide another layer. The FDA's guidance on electronic systems, records, and signatures states that electronic records and signatures used in clinical investigations should be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.

Data-quality requirements are also encouraging automated validation.

EDC systems can identify missing fields, inconsistent values, and protocol-related discrepancies during data entry. This reduces dependence on retrospective data cleaning.

Integration with other digital clinical systems creates another opportunity. The FDA has issued guidance supporting the use of digital health technologies for remote data acquisition in clinical investigations, reflecting broader movement toward digitally collected trial information.

“EDC platforms are becoming more than electronic case-report forms. Sponsors are evaluating them as controlled data environments that connect sites, CROs and clinical systems while preserving traceability,” said Shambhu Nath Jha, Principal Consultant at Fact.MR. “Platforms that combine rapid study configuration with validation, interoperability and regulatory-ready audit controls are positioned to gain preference.”

Cost and Integration Complexity Remain Barriers

The market still faces implementation challenges.

System validation can require significant time and specialized expertise, particularly for complex studies with multiple integrations.

Study configuration can also become difficult when protocols contain numerous conditional fields, amendments, data checks, and country-specific requirements.

Integration presents another challenge. Connecting EDC platforms with laboratory systems, EHRs, randomization technologies, ePRO platforms, and other applications can require additional technical work.

For smaller sponsors and investigator-led studies, these costs may influence platform selection and encourage demand for configurable SaaS solutions.

United States Leads Country Growth

The United States is projected to expand at an 11.8% CAGR from 2026 to 2036, the fastest growth among the countries profiled by Fact.MR.

The country's large clinical-research ecosystem and regulatory emphasis on electronic records support sustained demand for validated EDC platforms.

Germany follows at 11.3% CAGR, while Japan is projected to grow at 10.9%. The United Kingdom is forecast at 10.4%, Canada at 9.9%, Australia at 9.4%, and Singapore at 8.9% through 2036.

The differences between these markets reflect variations in clinical-trial activity, regulatory systems, digital infrastructure, and adoption of cloud-based research technologies.

Competitive Landscape

Key companies identified by Fact.MR include Veeva Systems Inc., Oracle Corporation, Medidata Solutions Inc., OpenClinica LLC, Castor EDC B.V., Clario, Dassault Systèmes SE, IBM Corporation, Anju Software Inc., and Fortrea Holdings Inc.

Competition spans broad clinical-development platforms and specialist EDC providers.

Large enterprise vendors can leverage integrations across clinical operations, data management, regulatory processes, and other life-sciences workflows. Specialist providers can compete through study-build speed, configurable forms, investigator usability, and support for academic or investigator-led research.

Interoperability is becoming increasingly important. Sponsors are assessing whether EDC platforms can exchange information with randomization systems, electronic patient-reported outcome tools, laboratory systems, and other clinical applications.

The ability to produce reliable, traceable and submission-ready datasets remains a central procurement criterion.

Electronic Data Capture Systems Market Snapshot

2025 market value: USD 2.4 billion
2026 market value: USD 2.7 billion
2036 projected value: USD 7.4 billion
CAGR, 2026–2036: 10.6%
Absolute opportunity: USD 4.7 billion
Leading solution type: Cloud-based EDC Platforms, 42.0%
Leading clinical application: Clinical Trial Data Management, 44.0%
Leading end-use industry: Pharmaceutical Companies, 46.0%
Leading user category: Clinical Research Organizations, 43.0%
Leading deployment model: SaaS Deployment, 41.0%
Fastest-growing profiled country: United States, 11.8% CAGR
Unlock 360° insights for strategic decision making and investment planning:https://www.factmr.com/report/electronic-data-capture-systems-market

Report Scope and Methodology

The Fact.MR study evaluates the electronic data capture systems market across solution type, clinical application, end-use industry, user category, deployment model, and region.

Solution types include cloud-based EDC platforms, on-premise EDC systems, mobile EDC platforms, and AI-enabled EDC platforms.

Clinical applications include clinical trial data management, patient data collection, real-world evidence studies, and decentralized clinical trials. End-use industries include pharmaceutical companies, academic research organizations, CROs, hospitals and clinics, and broader life-sciences organizations.

User categories include CROs, research hospitals, clinical trial sites, healthcare providers, and regulatory agencies. Deployment models cover SaaS, on-premise, private infrastructure, hybrid infrastructure, mobile-first platforms, and AI-assisted data validation.

The study covers North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa, with detailed country analysis for the United States, Germany, Japan, the United Kingdom, Canada, Australia, and Singapore.

Fact.MR states that the assessment draws on more than 120 sources, over 35 company portfolios, and more than 20 industry interviews across at least 25 countries, combining primary research, regulatory analysis, market sizing, forecasting, company assessment, and data validation.

Explore More Related Studies Published by Fact.MR Research:

Connective Tissue Disease Market- https://www.factmr.com/report/connective-tissue-disease-market

Laboratory Animal Medicine Market- https://www.factmr.com/report/laboratory-animal-medicine-market

Lifestyle Diseases Apps Market- https://www.factmr.com/report/lifestyle-diseases-apps-market

Longevity Wellness Pharmaceutical Market- https://www.factmr.com/report/longevity-wellness-pharmaceutical-market

Psychiatric Digital Biomarkers Market- https://www.factmr.com/report/psychiatric-digital-biomarkers-market

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, providing market intelligence and syndicated research across healthcare, food and beverage, consumer goods, technology, industrial goods, and other sectors. The company operates from offices in Rockville, Maryland, United States, and Dublin, Ireland.

Media Contact

Fact.MR
11140 Rockville Pike, Suite 400
Rockville, MD 20852, United States
Tel: +1 (628) 251-1583
Email: [email protected]

Suite 9884, 27 Upper Pembroke Street
Dublin 2, Ireland
Tel: +353-1-4434-232

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.